Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RAY004
- Development stage
- Preclinical
- Lead developer
- Raynovent Biotech
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
RAY004 is an oral small molecule Amylin receptor agonist under development by Raynovent Biotech (a subsidiary of Zhongsheng Pharmaceutical) for the treatment of metabolic diseases, including obesity and type 2 diabetes. It is currently in the preclinical/drug discovery stage. Historically, the code RAY004 was also associated with an early-stage 3C-like (3CL) protease inhibitor program for COVID-19 and influenza, but the company's current pipeline lists RAY004 as a metabolic disease candidate targeting the Amylin pathway.
02
Targets
AMY receptor (Calcitonin receptor (with ramps))Mpro (3C-like proteinase of SARS-CoV-2)
Beyond the preview
Go deeper on RAY004.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RAY004.